Last updated: 2026-09-18 14:18:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Merck & Co., Inc. (MRK) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $146.10, with a market capitalisation of $357.52B and a P/E ratio of 114.42. Over the past 52 weeks, its price has ranged from $77.58 to $156.92. This page covers its latest market performance, valuation, price trends and company information.
$357.52B | |
$147.08 | |
$156.92 | |
$15.32 | |
$147.15 | |
2.23M | |
10.17M | |
114.42 | |
$156.92 | |
$77.58 | |
2.29% | |
-- |
Merck & Co., Inc. (MRK) is currently trading at $146.10 as of 2026-09-18 14:02:58, down 0.72% ($1.05) from the previous close of $147.15
During today's regular trading session, MRK has traded between $15.32 and $156.92, with a trading volume of 2.23M shares. The current price is near the upper end of today's range.
Over the past seven days, Merck & Co., Inc. (MRK) moved from $147.53 to $146.10, representing a decline of 0.97% ($1.43).
The stock traded between $142.32 and $149.41 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 8.40 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 86.4%
MRK is currently trading at $146.10, placing it 86.4% of the way from its 52-week low of $77.58 to its 52-week high of $156.92. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 75000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Merck & Co., Inc. (MRK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.